Indian Pharmaceutical Alliance

IPA also refuted the study's reliance on the FDA Adverse Event Reporting System (FAERS) data, stating that FAERS data is observational and does not prove causation between drugs and adverse events.

Pharma bodies join hands to improve quality of pharmacy education

Indian Pharmaceutical Alliance, Pharmacy Council of India sign MoU to this effect. So far, 35 teachers have been trained under the first phase. The intention is to help build a competent workforce for the industry.

Drug samples, brand reminders to doctors should not be seen as gifts: Pharma body

The government is likely to revise the Uniform Code of Pharmaceutical Marketing Practices in 2023. 

Hike in cash aid for patients with rare diseases raises hopes for entry of new ‘orphan drugs’ in India

The change has come through a modification in the National Policy for Rare Diseases, which was first notified in 2021

Interview | Russia-Ukraine war piles stress on Indian pharma industry, says Sudarshan Jain of IPA

Indian drug makers should focus on raising the quality of their products to capture 5-6 percent of global pharma sales by 2030, says the secretary general of the Indian Pharmaceutical Alliance  

Veterans Unpacked | Sudarshan Jain: “Adopt technology very fast and find the time to understanding it as much as possible”

"Because the world is changing fast, so you have to be in learning mode: learn, unlearn and relearn."

Shipment of hydroxychloroquine to US likely to start next week: IPA

Hydroxychloroquine is being touted as a game changer in the fight against COVID-19 pandemic.

Why Scott Gottlieb, the new US FDA chief, could be good news for Indian drug makers

The US FDA appointment is closely watched by Indian pharmaceutical industry which supplies 40 percent of the generic medications consumed in the US. The generic or copycat drugs account for more than 8 in 10 prescriptions. India has 572 US FDA compliant plants -- the highest outside US.

Pharma group IPA hits out at local drug regulators

The Indian Pharmaceutical Alliance – a powerful grouping of twenty leading Indian drug companies – has written to Arvind Panagariya, vice chairman of the National Institution for Transforming India or NITI Aayog, expressing concerns over the recent decisions of the government.

Union Budget 2017-18: Do big drug cos stand to lose on proposed rejig of pharma rules?

Analysts who track the sector say that Jaitley‘s statement hints at government intention in making generic prescribing mandatory.

IACC Convention: Pharma & the USFDA jigsaw

Watch the interview of DG Shah, Habil Khorakiwala, KG Ananthakrishnan, Nandkumar Chodankar, SK Nanda, Sudhansh Pant to CNBC-TV18‘s Ekta Batra where they spoke about issues that standout in terms of India and America and the pharmaceutical sector.

IPA files contempt petition against NPPA

As far as the petition goes, the IPA has said that the NPPA has committed a contempt of court order with regard to the August 2014 order of the Bombay High Court where they said that no coercive action should be taken against any pharma company belonging to the IPA.

Govt allows pharma cos to hike rates of 509 essential drugs

The National Pharmaceutical Pricing Authority (NPPA) has issued a notification for price hike of drugs in line with the wholesale price index of 2014 under Drug Price Control Order, 2013.

Here's who competed for the coveted India Healthcare Awards

India is all set to become one of the top economies of the world and Asia‘s next super power. India‘s growing market of 1.2 billion people with an average age of 25 an economy capable of generating a GDP of 8.5% and a middle-class of 250 million people have experts‘ confidence that India will grow rapidly in coming decade.

IPA hits back at Pfizer; says no discrimination with US cos

The Indian Pharmaceutical Alliance hit back at international drug major Pfizer by stating that India's business environment for pharma companies had not been biased.

Pharma pricing policy is bitter pill for biz, public: Shah

DG Shah, secretary-general, Indian Pharmaceutical Alliance explains to CNBC-TV18 that the new pharma pricing adopted by the government would offer less effective drugs to consumers, stifle the growth of research and development in India and stall overseas investment.

Drug cos want market based pricing but may hurt consumers

With GoM set to take a call on framing the drug pricing policy, India's largest association of pharma companies has submitted a study to show the pricing formula should be market based. But critics say this could end up in increasing drug prices reports CNBC-TV18's Archana Shukla.

Compulsory licencing: Should govt tighten norms in pharma?

The Department of Industrial Policy and Promotion (DIPP) had put out a discussion paper dealing with compulsory licenses for the pharmaceutical sector. DG Shah, secretary general, Indian Pharmaceutical Alliance, speaks about the issue.